Diagnostic and prognostic significance of lysophosphatidic acid in malignant pleural effusions

Journal of Thoracic Disease

Volumn 6, Issue 5, 2014, Pages 483-490

  Bai, Cui Qing ^a   Yao, Yan Wen ^b   Liu, Chun Hua ^b   Zhang, He ^c   Xu, Xiao Bing ^d   Zeng, Jun Li ^a   Liang, Wen Jun ^b   Yang, Wen ^b   Song, Yong ^a,b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^c WANNAN MEDICAL COLLEGE   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Diagnosis; Lung cancer; Lysopohsphatidic acid (LPA); Malignant pleural effusions (MPEs); Prognosis

Indexed keywords

LYSOPHOSPHATIDIC ACID; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; BENIGN PLEURA EFFUSION; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT PLEURA EFFUSION; OVERALL SURVIVAL; PHOSPHOLIPID BLOOD LEVEL; PLEURA EFFUSION; PNEUMONIA; PROGRESSION FREE SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUBERCULOUS PLEURISY;

EID: 84900470400     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2014.02.14     Document Type: Article

References (20)

1. American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000;162:1987-2001.
2. Stathopoulos GT, Psallidas I, Moustaki A, et al. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J Natl Cancer Inst 2008;100:1464-76.
3. Martínez-Moragón E, Aparicio J, Sanchis J, et al. Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration 1998;65:108-13.
4. Yoneda KY, Mathur PN, Gasparini S. The evolving role of interventional pulmonary in the interdisciplinary approach to the staging and management of lung cancer. Part III: diagnosis and management of malignant pleural effusions. Clin Lung Cancer 2007;8:535-47.
5. Naito T, Satoh H, Ishikawa H, et al. Pleural effusion as a significant prognostic factor in non-small cell lung cancer. Anticancer Res 1997;17:4743-6.
6. Khaleeq G, Musani AI. Emerging paradigms in the management of malignant pleural effusions. Respir Med 2008;102:939-48.
7. Tomita M, Shimizu T, Ayabe T, et al. Carcinoembryonic antigen level in serum and pleural lavage fluid in non-small cell lung cancer. Thorac Cardiovasc Surg 2010;58:350-3.
8. Sumi M, Kagohashi K, Satoh H, et al. Endostatin levels in exudative pleural effusions. Lung 2003;181:329-34.
9. Chen Y, Ramakrishnan DP, Ren B. Regulation of angiogenesis by phospholipid lysophosphatidic acid. Front Biosci (Landmark Ed) 2013;18:852-61.
10. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003;3:582-91.
11. Murph MM, Hurst-Kennedy J, Newton V, et al. Lysophosphatidic acid decreases the nuclear localization and cellular abundance of the p53 tumor suppressor in A549 lung carcinoma cells. Mol Cancer Res 2007;5:1201-11.
12. Westermann AM, Havik E, Postma FR, et al. Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol 1998;9:437-42.
13. Aoki J. Mechanisms of lysophosphatidic acid production. Semin Cell Dev Biol 2004;15:477-89.
14. Jalink K, Eichholtz T, Postma FR, et al. Lysophosphatidic acid induces neuronal shape changes via a novel, receptormediated signaling pathway: similarity to thrombin action. Cell Growth Differ 1993;4:247-55.
15. Shi HZ, Liang QL, Jiang J, et al. Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. Respirology 2008;13:518-27.
16. Liang QL, Shi HZ, Qin XJ, et al. Diagnostic accuracy of tumour markers for malignant pleural effusion: a metaanalysis. Thorax 2008;63:35-41.
17. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
18. Hu YL, Tee MK, Goetzl EJ, et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst 2001;93:762-8.
19. Song Y, Wu J, Oyesanya RA, et al. Sp-1 and c-Myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxia-inducible factor-1-independent mechanism. Clin Cancer Res 2009;15:492-501.
20. Xu X, Prestwich GD. Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model. Cancer 2010;116:1739-50.